Protara Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No trades yet today.
No trades yet today.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Protara Therapeutics, Inc.'s 5 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; of Protara Therapeutics, Inc.'s 5 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 10 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Protara Therapeutics, Inc.
2.42
pre 2.32 −3.73%
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
−4.87%
vs ±21.5% implied · ×0.23
shaded = implied · ▲▼ = realized
Bull1
Bear1
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $17.9M | 10.18% | — |
| BlackRockindex-like | $14.0M | 7.95% | +7.91% |
| Millennium | $11.8M | 6.73% | +9.54% |
| Velan Capital | $10.9M | 6.17% | +0.35% |
| Vanguardindex-like | $8.8M | 4.99% | +8.55% |
| Manager | Value | % base | |
|---|---|---|---|
| Jupiter Topco | $17.9M | 10.18% | — |
| BlackRockindex-like | $14.0M | 7.95% | +7.91% |
| Millennium | $11.8M | 6.73% | +9.54% |
| Velan Capital | $10.9M | 6.17% | +0.35% |
| Vanguardindex-like | $8.8M | 4.99% | +8.55% |
Expected move
No implied move.